|
|
Vaccine Detail
|
AUT-OV-ALVAC-hB7.1 Vaccine |
| Vaccine Information |
- Vaccine Name: AUT-OV-ALVAC-hB7.1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007274
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- env
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CD86
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The treatment is a recombinant ALVAC-HIV-1 vaccine expressing Gag, Pol, and gp160 in a prime-boost protocol with their homologous vaccine native Env proteins (Pal et al., 2006).
- Description: A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1. (NCIT_C28682).
This vaccine has been used in trials involving Recurrent Ovarian Epithelial Cancer. NCT00004032
|
| Host Response |
|
|
| References |
NCIT_C28682: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28682]
Pal et al., 2006: Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. Journal of virology. 2006; 80(8); 3732-3742. [PubMed: 16571790].
|
|
